The End Of Just-In-Time? Why Clinical Trial Supply Chains Are Rethinking Inventory Strategy

By Laura Hay, senior director of global program management, Trax Group | 2025 Winner, everywoman Customer/Passenger (Leader) Award

For decades, supply chains have focused on efficiency. Organizations optimized inventory levels, reduced excess stock, streamlined distribution networks, and built processes designed around predictable demand. The goal was clear: minimize waste while ensuring products were available when needed. In many industries, this approach became known as just-in-time inventory management.

However, clinical trial supply chains operate in a very different environment.

The cost of being wrong is not simply an operational delay. A supply shortage can impact clinical sites, disrupt trial timelines, and create challenges for patients relying on consistent access to investigational therapies.

As clinical trials become more global, complex, and unpredictable, organizations are beginning to rethink whether traditional inventory strategies are still effective. The question is no longer, “How little inventory can we carry?” The question has become, “How do we create enough flexibility to protect patients while maintaining operational efficiency?”

Clinical trial supply chains are entering a new era of agile inventory management.

The Challenge With Traditional Inventory Models

Traditional inventory planning often relies on assumptions about demand stability. Forecasts are created based on expected enrollment timelines, patient recruitment projections, and planned study milestones. Inventory is positioned according to these assumptions, and supply strategies are built around the expectation that conditions will remain relatively consistent. But clinical trials rarely follow a perfectly predictable path. Enrollment can accelerate unexpectedly. Site activation timelines can change. Protocol amendments can impact demand. Regulatory decisions can shift timelines. Global events can create transportation or manufacturing disruptions.

When supply strategies are built around fixed assumptions, even small changes can create significant operational pressure. A trial enrolling faster than expected may suddenly require additional packaging capacity. A regional enrollment shift may create inventory imbalances between depots. A transportation delay may put pressure on available stock and increase the risk of missed dosing windows.

The challenge is not that forecasting is ineffective. The challenge is that forecasting alone is no longer enough.

The Need For More Adaptive Inventory Strategies

The future of clinical supply planning requires a move away from static inventory decisions toward more dynamic approaches.

Agile inventory management focuses on creating flexibility within the supply chain so organizations can adapt as trial conditions change. This requires a deeper understanding of:

• Where inventory is positioned across global networks.
• How quickly demand patterns are changing.
• Which regions may require additional support.
• How manufacturing and packaging timelines impact availability.
• Where potential supply risks may develop.

Instead of simply building inventory based on the original forecast, organizations can continuously evaluate changing conditions and adjust supply strategies accordingly. This creates a more responsive model where inventory decisions are based on current intelligence rather than outdated assumptions.

Visibility Is The Foundation Of Inventory Agility

The ability to manage inventory dynamically depends on visibility. Clinical supply teams need to understand not only how much product exists, but where it is located, how quickly it can be moved, and whether it aligns with future patient demand. This requires connected data across multiple systems, including RTSM/IRT platforms, ERP systems, inventory management tools, depot operations, and logistics networks. Without this connection, organizations may experience conflicting views of inventory availability.

One system may indicate sufficient stock based on historical demand. Another may show changing patient requirements. A depot may have physical inventory that does not align with the latest enrollment trends. These gaps create uncertainty. And when organizations lack confidence in their data, they often compensate by adding additional inventory buffers. While safety stock can provide protection, excessive buffering can create unnecessary costs, increase expiry risk, and reduce supply chain flexibility.

The goal is not simply more inventory. The goal is better-informed inventory decisions.

Expiry And Waste Are Growing Supply Chain Concerns

One of the most overlooked challenges in clinical trial supply is the relationship between inventory strategy and product waste. Investigational products often have limited shelf lives, and excessive inventory can create unnecessary expiry exposure.

When organizations overestimate demand or package too much product too early, they may create inventory that cannot be used before expiration. This creates financial impact, operational inefficiency, and additional complexity in managing returns and destruction. A more agile approach allows organizations to better align supply with actual patient needs. By improving forecasting accuracy, monitoring demand changes, and adjusting inventory positioning, companies can reduce waste while still protecting trial continuity.

AI And Predictive Analytics Are Changing Inventory Management

Technology is creating new opportunities to improve how organizations manage clinical trial inventory. Artificial intelligence and advanced analytics can help identify patterns that may not be immediately visible through traditional reporting.

Predictive models can analyze:

• enrollment trends
• inventory consumption rates
• regional demand shifts
• supply risks
• transportation performance
• manufacturing timelines.

These insights allow teams to identify potential shortages or excess inventory earlier and make proactive adjustments.

The value of AI is not replacing supply chain expertise. The value is giving experienced teams better information to make faster, more informed decisions. The combination of human expertise and predictive intelligence creates a more resilient approach to clinical supply management.

The Future Of Clinical Supply Is Flexibility

The clinical trial supply chains of the future will not be defined by having the lowest inventory levels. They will be defined by their ability to adapt. Efficiency will always matter, but efficiency without resilience creates vulnerability. The most successful organizations will find the balance between controlling cost and maintaining the flexibility needed to support changing clinical environments.

Agile inventory strategies allow organizations to respond to uncertainty without relying on excessive buffers or emergency solutions. They create supply chains that are more efficient, more sustainable, and better prepared for unexpected change, because in clinical trials, inventory management is not only about products sitting on shelves. It is about ensuring the right therapy reaches the right patient at the right time. And that requires a supply chain built not just for today’s forecast but for tomorrow’s uncertainty.

About The Author:

Laura Hay is a global supply chain leader specializing in program management, customer success, and account strategy. She has a proven track record of leading cross-functional teams to deliver complex, high-impact initiatives on time and within budget. Laura is known for building strong stakeholder relationships, driving operational excellence, and managing multimillion-dollar programs. She is passionate about connecting people, processes, and technology to build scalable, resilient supply chain solutions that deliver measurable business impact.